Answers are grounded in this paper and cite their sources.
BACKGROUND AND PURPOSE: species. MATERIALS AND METHODS: Whole blood samples were collected twice, from 72 patients for Real Time PCR and blood culture assays. The primers and hybridization probes were designed to potentiate the specific sequence of 18S rRNA genes using Light Cycler system and Fluorescence Resonance Energy Transfer (FERT). The patients with hematologic malignancies and bone marrow transplant recipients were evaluated for IC based on the revised European Organization for Research and Treatment of Cancer/ Mycoses Study Group (EORTC/MSG) criteria. RESULTS: (9%) were identified. According to the revised EORTC / MSG, 1 patient (9%) and 10 patients (91%) were defined as proven and possible groups of IC, respectively. The mortality rate in proven and possible IC patient was found 54.5%. CONCLUSION: species DNA and the management of patients suffering from hematologic malignancies and bone marrow recipient are at risk for IC.
No takes yet. Share an insight, caveat, or question.
Ashrafi et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: